We are enabling deeper access to in vivo biology and driving durable and potentially transformational research on disease in a new era of advanced medicine. We believe our platform is the first to employ both proteomics, or the study of proteins and their functions, and single cell biology in an effort to fully characterize and link cellular function to patient outcomes by revealing treatment response and disease progression.
Lead Underwriter
Cowen and Company, LLC, Evercore Group L.L.C, Morgan Stanley & Co. LLC, SVB Leerink LLC
